Related Experiment Videos
[Hepatitis C and HIV coinfection. Current aspects of therapy]
1Universitätsklinik und Poliklinik I, Universitätsklinikum Bonn. rockstroh@uni-bonn.de
Insights
Hepatitis C (HCV) progresses faster in patients with HIV/HCV coinfection, increasing liver failure risks. New pegylated interferon and ribavirin treatments show promising response rates around 50% for these patients.
Area of Science:
- Hepatology
- Infectious Diseases
- Immunology
Background:
- HIV/HCV coinfection accelerates hepatitis C progression, leading to cirrhosis and increased mortality.
- Hepatitis C negatively impacts HIV progression, highlighting the need for effective treatments in coinfected individuals.
Purpose of the Study:
- To evaluate the efficacy of pegylated interferon and ribavirin in treating hepatitis C among patients coinfected with HIV.
- To compare treatment outcomes with standard interferon/ribavirin therapy.
Main Methods:
- Clinical trials involving HIV-coinfected patients undergoing treatment for hepatitis C.
- Administration of pegylated interferon and ribavirin therapy.
Main Results:
- Initial trials reported primary response rates of approximately 50% for pegylated interferon and ribavirin.
- These response rates are significantly better than those observed with non-modified interferon/ribavirin therapy in similar patient cohorts.
Conclusions:
- Pegylated interferon and ribavirin demonstrate improved efficacy in treating hepatitis C in HIV-coinfected patients.
- Further research and treatment development are warranted to optimize outcomes for this vulnerable population.
Abstract:
HIV/HCV coinfection is characterized by a progredient course of hepatitis C. A more rapid development to cirrhosis, and especially in the presence of progredient immunodeficiency, an increased mortality due to liver failure has been described in coinfected patients. In addition hepatitis C has an unfavorable impact on the progression of HIV. The worse course of hepatitis C in HIV-coinfected patients as well as the faster progression of HIV underline the need for development of treatment options for hepatitis C in HIV-coinfected patients. First results from trials looking at the effect of pegylated interferon and ribavirin for treatment of hepatitis C in HIV-coinfected patients found primary response rates of around 50% which were clearly better than the response rates observed under non-modified interferon/ribavirin therapy in HIV/HCV-coinfected patients so far.